[旨在实现癌症新型高效治疗的转化生长因子-β靶向免疫疗法] - Suppr

Suppr

超能文献

[TGF-β-targeted immunotherapy aiming for new and efficient treatments of cancer].

作者信息

Foughali Rayan, Marie Julien C

机构信息

Master de cancérologie, ISPB, Université Claude Bernard Lyon 1, Lyon 69008, France.

Tumor escape resistance immunity department, Cancer research center of Lyon, Lyon 69008, France.

出版信息

Med Sci (Paris). 2020 Jan;36(1):77-79. doi: 10.1051/medsci/2019261. Epub 2020 Feb 4.

DOI:10.1051/medsci/2019261

PMID:32014103

Abstract

摘要

相似文献

[TGF-β-targeted immunotherapy aiming for new and efficient treatments of cancer].

Med Sci (Paris). 2020 Jan;36(1):77-79. doi: 10.1051/medsci/2019261. Epub 2020 Feb 4.

[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge].

Med Sci (Paris). 2017 Jun-Jul;33(6-7):563-564. doi: 10.1051/medsci/20173306001. Epub 2017 Jul 19.

[Neutrophils and cancer: discovery of a new mechanism of cellular toxicity and therapeutic perspectives].

Med Sci (Paris). 2020 Jan;36(1):80-82. doi: 10.1051/medsci/2019262. Epub 2020 Feb 4.

[Bispecific antibodies, novel therapeutic candidates harnessing the immune system].

Med Sci (Paris). 2019 Dec;35(12):1072-1082. doi: 10.1051/medsci/2019242. Epub 2020 Jan 6.

Seeking and Exploring Efficient Ways to Target Cancer.

Cells. 2020 Sep 17;9(9):2117. doi: 10.3390/cells9092117.

[New treatments for metastatic melanoma: a first hope].

Rev Prat. 2011 Nov;61(9 Suppl):S1-2.

Emerging therapeutics in refractory renal cell carcinoma.

Expert Opin Pharmacother. 2016 Jun;17(9):1225-32. doi: 10.1080/14656566.2016.1182987. Epub 2016 May 23.

[Non-mutated neoantigens, TEIPP, as new targets for cancer immunotherapies].

Med Sci (Paris). 2020 Jan;36(1):83-86. doi: 10.1051/medsci/2019263. Epub 2020 Feb 4.

Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.

Cancer. 2018 Oct 1;124(19):3819-3829. doi: 10.1002/cncr.31517. Epub 2018 May 3.

Phase I trials as valid therapeutic options for patients with cancer.

Nat Rev Clin Oncol. 2019 Dec;16(12):773-778. doi: 10.1038/s41571-019-0262-9. Epub 2019 Sep 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[TGF-β-targeted immunotherapy aiming for new and efficient treatments of cancer].

作者信息

Foughali Rayan, Marie Julien C

机构信息

Master de cancérologie, ISPB, Université Claude Bernard Lyon 1, Lyon 69008, France.

Tumor escape resistance immunity department, Cancer research center of Lyon, Lyon 69008, France.

出版信息

Med Sci (Paris). 2020 Jan;36(1):77-79. doi: 10.1051/medsci/2019261. Epub 2020 Feb 4.

DOI:10.1051/medsci/2019261

PMID:32014103

Abstract

摘要

相似文献

[TGF-β-targeted immunotherapy aiming for new and efficient treatments of cancer].

Med Sci (Paris). 2020 Jan;36(1):77-79. doi: 10.1051/medsci/2019261. Epub 2020 Feb 4.

[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge].

Med Sci (Paris). 2017 Jun-Jul;33(6-7):563-564. doi: 10.1051/medsci/20173306001. Epub 2017 Jul 19.

[Neutrophils and cancer: discovery of a new mechanism of cellular toxicity and therapeutic perspectives].

Med Sci (Paris). 2020 Jan;36(1):80-82. doi: 10.1051/medsci/2019262. Epub 2020 Feb 4.

[Bispecific antibodies, novel therapeutic candidates harnessing the immune system].

Med Sci (Paris). 2019 Dec;35(12):1072-1082. doi: 10.1051/medsci/2019242. Epub 2020 Jan 6.

Seeking and Exploring Efficient Ways to Target Cancer.

Cells. 2020 Sep 17;9(9):2117. doi: 10.3390/cells9092117.

[New treatments for metastatic melanoma: a first hope].

Rev Prat. 2011 Nov;61(9 Suppl):S1-2.

Emerging therapeutics in refractory renal cell carcinoma.

Expert Opin Pharmacother. 2016 Jun;17(9):1225-32. doi: 10.1080/14656566.2016.1182987. Epub 2016 May 23.

[Non-mutated neoantigens, TEIPP, as new targets for cancer immunotherapies].

Med Sci (Paris). 2020 Jan;36(1):83-86. doi: 10.1051/medsci/2019263. Epub 2020 Feb 4.

Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.

Cancer. 2018 Oct 1;124(19):3819-3829. doi: 10.1002/cncr.31517. Epub 2018 May 3.

Phase I trials as valid therapeutic options for patients with cancer.

Nat Rev Clin Oncol. 2019 Dec;16(12):773-778. doi: 10.1038/s41571-019-0262-9. Epub 2019 Sep 2.